Baizhou Li
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
-
- Lung Cancer Treatments and Mutations 7
- Lung Cancer Diagnosis and Treatment 5
- Oncology 11
- Cancer Immunotherapy and Biomarkers 4
- Co-authors
- Jia Fan (2 shared papers)Shuang‐Jian Qiu (2 shared papers)Qiang Gao (2 shared papers)Masayuki Sho (1 shared paper)Xiaoying Wang (1 shared paper)Yang Xu (1 shared paper)Jian Zhou (1 shared paper)Yoshiyuki Nakajima (1 shared paper)
- Journals
- Frontiers in Oncology (3 papers)Nature (2 papers)IEEE Access (2 papers)Cancers (2 papers)Technology Analysis and Strategic Management (2 papers)
- Partner nations
- ChinaUnited StatesEthiopia
In The Last Decade
Baizhou Li
47 papers receiving 1.6k citations
Baizhou Li's Hit Papers
Peers
Comparison fields: 5 of 139
- Oncology 663
- Hepatology 191
- Immunology 507
- Cancer Research 140
- Pulmonary and Respiratory Medicine 239
Countries citing papers authored by Baizhou Li
This map shows the geographic impact of Baizhou Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baizhou Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baizhou Li more than expected).
Fields of papers citing papers by Baizhou Li
This network shows the impact of papers produced by Baizhou Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baizhou Li. The network helps show where Baizhou Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Baizhou Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 52 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma Hit paper breakdown → | 2009 | 663 |
| 2 | 2020 | 212 | |
| 3 | 2022 | 83 | |
| 4 | 2022 | 73 | |
| 5 | 2020 | 58 | |
| 6 | 2020 | 51 | |
| 7 | 2021 | 39 | |
| 8 | 2024 | 38 | |
| 9 | 2011 | 35 | |
| 10 | 2020 | 30 | |
| 11 | 2022 | 30 | |
| 12 | 2021 | 27 | |
| 13 | 2020 | 25 | |
| 14 | 2021 | 19 | |
| 15 | 2010 | 17 | |
| 16 | 2023 | 16 | |
| 17 | 2022 | 14 | |
| 18 | Melanotic schwannoma of thoracic spinal root mimics metastatic melanoma: a potential pitfall for misdiagnosis. | 2015 | 13 |
| 19 | 2021 | 12 | |
| 20 | 2020 | 11 |
About Baizhou Li
Baizhou Li is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Pathology and Forensic Medicine, Economics and Econometrics and Molecular Biology, having authored 52 papers that have together received 1.6k indexed citations. Recurring topics across this work include Energy, Environment, Economic Growth (8 papers), Lung Cancer Treatments and Mutations (7 papers), Lymphoma Diagnosis and Treatment (5 papers), Lung Cancer Diagnosis and Treatment (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Neurofibromatosis and Schwannoma Cases (4 papers), Qualitative Comparative Analysis Research (3 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Oncology (663 citations), Hepatology (191 citations), Immunology (507 citations), Cancer Research (140 citations) and Pulmonary and Respiratory Medicine (239 citations). Baizhou Li has collaborated with scholars based in China, United States and Ethiopia. Frequent co-authors include Jia Fan, Shuang‐Jian Qiu, Qiang Gao, Masayuki Sho, Xiaoying Wang, Yang Xu, Jian Zhou, Yoshiyuki Nakajima, Yongyong Shi and Yongsheng Xiao. Their work appears in journals such as Frontiers in Oncology, Nature, IEEE Access, Cancers and Technology Analysis and Strategic Management.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.